Table 1.
Clinicopathological characteristics of endometrial cancers regarding POLE and MMR status. One-way ANOVA, Unpaired t test, Chi-square test and Fisher’s Exact test were used and p<0.05 was considered as statistical significance.
| ALL(n = 202) | POLEm (n = 24) | MMRd(n = 38) | MMRp(n = 140) | P value(POLEm, MMRd, MMRp) | P value(POLEm vs MMRp) | P value(MMRd vs MMRp) | |
|---|---|---|---|---|---|---|---|
|
Age at diagnosis,
Mean (range) |
56.3 (23–82) |
51.9 (23–72) |
58.3 (41–75) |
56.5 (29–82) |
0.2278 | 0.0658 | 0.9499 |
| Histology subtypes | 202 | 24(11.9%) | 38(18.8%) | 140(69.3%) | |||
| Endometrioid | 190 | 22(11.6%) | 36(18.9%) | 132(69.5%) | 0.865 | 0.6415 | >0.9999 |
| Non-endometrioid | 12 | 2(16.7%) | 2(16.7%) | 8(66.7%) | |||
| grade | 197 | 24(12.2%) | 38(19.3%) | 135(68.5%) | |||
| 1 | 88 | 7(7.9%) | 16(18.2%) | 65(73.9%) | 0.2127 | 0.1187 | 0.5826 |
| 2 | 69 | 12(17.4%) | 9(13.0%) | 48(69.6%) | 0.1039 | 0.2526 | 0.2407 |
| 3 | 40 | 5(12.5%) | 13(32.5%) | 22(55%) | 0.0527 | 0.5628 | 0.0218 |
| Stage | 189 | 21(11.1%) | 37(19.6%) | 131(69.3%) | |||
| I | 143 | 14(9.8%) | 24(16.8%) | 105(73.4%) | 0.2540(early stages vs late stages) | 0.1533(early stages vs late stages) | 0.3589(early stages vs late stages) |
| II | 4 | 0 | 3(75%) | 1(25%) | |||
| III | 32 | 5(15.6%) | 9(28.1%) | 18(56.2%) | |||
| IV | 10 | 2(20%) | 1(10%) | 7(70%) | |||
| Total number of early stages | 147 | 14(9.5%) | 27(18.4%) | 106(72.1%) | |||
| Total number of late stages | 42 | 7(16.7%) | 10(23.8%) | 25(59.5%) | |||
| Adjuvant therapy | 202 | 24(11.9%) | 38(18.8%) | 140(69.3%) | |||
| Any adjuvant therapy (platinum-based chemotherapy, radiotherapy) | 78 | 12(15.4%) | 21(26.9%) | 45(57.7%) | 0.0163 | 0.1065 | 0.0132 |
| No further treatment | 124 | 12(9.7%) | 17(13.7%) | 95(76.6%) |
POLEm, POLE mutation; MMRd, MMR deficiency; MMRp, MMR proficiency.
Data presented as no. (%). Missing data: stage for 13 patients, and grade for five patients.